Health Economics›Anaplastic glioma›First-line therapy

First-line therapy

Anaplastic glioma · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Temozolomide, then Temozolomide and RT, then Temozolomide N/A - protocol	—	R 23 791	28d	—	—	~4	~R 77 996 indirect	—
Temozolomide and RT Variant #01	—	R 19 131	45d	~7.9 mo	~18.7 mo	~12	~R 59 601 PFS proxy · indirect	7
Temozolomide and RT, then Temozolomide Variant #01	—	R 14 716	56d	—	—	~10	~R 58 865 indirect	—
RT, then Temozolomide Variant #01	—	R 8 584	77d	—	—	11	R 57 639 PFS proxy	2
Temozolomide monotherapy Variant #02	—	R 7 358	14d	—	8.6 mo	26	R 129 994 PFS proxy	1
PCV Variant #02 Partial	—	R 327	56d	—	49.8 mo	6	R 1 959 PFS proxy	2
RT, then Carmustine Variant #01 Partial	—	—	49d	—	—	~1	—	—
Carmustine monotherapy Variant #01 Partial	—	—	42d	—	—	~1	—	—
Radiation therapy N/A - radiation	—	—	49d	~46.0 mo	~7.5 mo	—	—	8
Observation Partial	—	—	—	—	31.2 mo	—	—	3

10 of 10 regimens shown